中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2012年
31期
2219-2221
,共3页
维甲酸%乳腺肿瘤%细胞分裂
維甲痠%乳腺腫瘤%細胞分裂
유갑산%유선종류%세포분렬
All trans retinoic acid%Breast neoplasms%Cell division
目的 观察全反式维甲酸(ATRA)对人MDA-MB-468和MCF-7乳腺癌细胞株细胞增殖和BP1表达的影响.方法 应用MTF法检测ATRA对人乳腺癌MDA-MB-468和MCF-7细胞株细胞增殖的影响,应用RT-PCR和免疫细胞化学方法检测10-5 mol/L的ATRA作用后其BP1基因的表达水平变化.结果 经ATRA作用后人乳腺癌细胞出现增殖抑制,BP1表达水平下降,各时间组细胞BP1 mRNA电泳条带光密度比率(ODR)值由作用前的0.85±0.01和0.71±0.01分别下降至作用24 h后为0.75±0.02和0.72 ±0.06,48 h后为0.55 ±0.01和0.52±0.05,72 h后为0.34±0.02和0.48±0.03,同种细胞各时间组间差异有统计学意义(P ＜0.01)；BP1蛋白阳性细胞的MOD值由作用前的0.830±0.017和0.860±0.090分别降至24 h后为0.509 ±0.081和0.826 ±0.015,48 h后为0.270±0.022和0.641±0.041,72 h后为0.145±0.019和0.206±0.179,同种细胞各时间组间显著性差异有统计学意义(P＜0.01).结论 ATRA能够抑制两种入乳腺癌细胞的增殖和BP1基因的表达.BP1可能作为ATRA抑制乳腺癌细胞生长的一个靶点.
目的 觀察全反式維甲痠(ATRA)對人MDA-MB-468和MCF-7乳腺癌細胞株細胞增殖和BP1錶達的影響.方法 應用MTF法檢測ATRA對人乳腺癌MDA-MB-468和MCF-7細胞株細胞增殖的影響,應用RT-PCR和免疫細胞化學方法檢測10-5 mol/L的ATRA作用後其BP1基因的錶達水平變化.結果 經ATRA作用後人乳腺癌細胞齣現增殖抑製,BP1錶達水平下降,各時間組細胞BP1 mRNA電泳條帶光密度比率(ODR)值由作用前的0.85±0.01和0.71±0.01分彆下降至作用24 h後為0.75±0.02和0.72 ±0.06,48 h後為0.55 ±0.01和0.52±0.05,72 h後為0.34±0.02和0.48±0.03,同種細胞各時間組間差異有統計學意義(P ＜0.01)；BP1蛋白暘性細胞的MOD值由作用前的0.830±0.017和0.860±0.090分彆降至24 h後為0.509 ±0.081和0.826 ±0.015,48 h後為0.270±0.022和0.641±0.041,72 h後為0.145±0.019和0.206±0.179,同種細胞各時間組間顯著性差異有統計學意義(P＜0.01).結論 ATRA能夠抑製兩種入乳腺癌細胞的增殖和BP1基因的錶達.BP1可能作為ATRA抑製乳腺癌細胞生長的一箇靶點.
목적 관찰전반식유갑산(ATRA)대인MDA-MB-468화MCF-7유선암세포주세포증식화BP1표체적영향.방법 응용MTF법검측ATRA대인유선암MDA-MB-468화MCF-7세포주세포증식적영향,응용RT-PCR화면역세포화학방법검측10-5 mol/L적ATRA작용후기BP1기인적표체수평변화.결과 경ATRA작용후인유선암세포출현증식억제,BP1표체수평하강,각시간조세포BP1 mRNA전영조대광밀도비솔(ODR)치유작용전적0.85±0.01화0.71±0.01분별하강지작용24 h후위0.75±0.02화0.72 ±0.06,48 h후위0.55 ±0.01화0.52±0.05,72 h후위0.34±0.02화0.48±0.03,동충세포각시간조간차이유통계학의의(P ＜0.01)；BP1단백양성세포적MOD치유작용전적0.830±0.017화0.860±0.090분별강지24 h후위0.509 ±0.081화0.826 ±0.015,48 h후위0.270±0.022화0.641±0.041,72 h후위0.145±0.019화0.206±0.179,동충세포각시간조간현저성차이유통계학의의(P＜0.01).결론 ATRA능구억제량충입유선암세포적증식화BP1기인적표체.BP1가능작위ATRA억제유선암세포생장적일개파점.
Objective To explore the effects of all trans retinoic acid (ATRA) on the cell proliferation and expression alterations of beta-protein 1 (BP1) in human breast cancer cells lines of MDA-MB-468 and MCF-7.Method The proliferation changes were detected by thiazolyl blue tetrazolium bromide (MTT) after the treatment of ATRA.At the dose of 10 -5 mol/L ATRA,the expression of BP1 was measured by reverse transcription-polymerase chain reaction (RT-PCR) and immunochemistry.Results After the treatment of ATRA,the proliferation of cells and the expression of BP1 decreased.Optical density ratio (ODR) of each group decreased from 0.85 ±0.01,0.71 ±0.01 to 0.75 ±0.02,0.72 ±0.06 at 24 h,0.55 ± 0.01,0.52 ± 0.05 at 48 h and 0.34 ± 0.02,0.48 ± 0.03 at 72 h.Significant differences existed among different time groups ( P ＜ 0.01 ).The mean optical density ( MOD ) of each group decreased from 0.509 ±0.081,0.826 ± 0.015 to 0.509 ± 0.081,0.826 ± 0.015 at 24 h,0.270 ± 0.022,0.641 ± 0.041at 48 h and 0.145 ±0.019 and 0.206 ±0.179 at 72 h.Significant differences existed among different time groups(P ＜ 0.01 ).Conclusion ATRA can inhibit the proliferation and the expression of BP1 in breast cancer cells.And BP1 gene may become a therapeutic target for the ATRA-mediated inhibited growth of breast cancer cells.
